Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon.
Joseph AllencherrilHani JneidDan AtarMahboob AlamGlenn LevineRobert A KlonerYochai BirnbaumPublished in: Cardiovascular drugs and therapy (2020)
Successful reperfusion of an infarct-related coronary artery by primary percutaneous intervention or fibrinolysis during acute ST-elevation myocardial infarction (STEMI) does not always restore myocardial tissue perfusion, a phenomenon termed "no-reflow." Herein we discuss the pathophysiology of this highly prevalent phenomenon and highlight the most salient aspects of its clinical diagnosis and management as well as the limitations of presently used methods. There is a great need for understanding the dynamic nature of no-reflow, as its occurrence is associated with poor cardiovascular outcomes. The no-reflow phenomenon may lend an explanation to the lack of further improvements in in-hospital mortality in STEMI patients despite decreases in door-to-balloon time. Hence, no-reflow potentially presents an important target for investigators interested in improving outcomes in STEMI.
Keyphrases
- st elevation myocardial infarction
- percutaneous coronary intervention
- acute myocardial infarction
- coronary artery
- st segment elevation myocardial infarction
- end stage renal disease
- acute coronary syndrome
- coronary artery disease
- ejection fraction
- randomized controlled trial
- chronic kidney disease
- newly diagnosed
- risk assessment
- minimally invasive
- pulmonary artery
- liver failure
- prognostic factors
- peritoneal dialysis
- type diabetes
- respiratory failure
- ultrasound guided
- magnetic resonance imaging
- patient reported outcomes
- metabolic syndrome
- cerebral ischemia
- radiofrequency ablation
- patient reported
- contrast enhanced
- hepatitis b virus
- acute respiratory distress syndrome
- computed tomography
- aortic dissection
- acute ischemic stroke